{"generic":"Iopamidol","drugs":["Iopamidol","Isovue-200","Isovue-250","Isovue-300","Isovue-370","Isovue-M 200","Isovue-M 300"],"mono":{"0":{"id":"6ii8s0","title":"Generic Names","mono":"Iopamidol"},"1":{"id":"6ii8s1","title":"Dosing and Indications","sub":{"0":{"id":"6ii8s1b4","title":"Adult Dosing","mono":"<ul><li>ISOVUE(R)-200, 250, 300 and 370 are not for intrathecal use and special attention must be given to insure that these products are not inadvertently administered intrathecally; ISOVUE-M(R) 200 and 300 are approved for intrathecal use<\/li><li>meticulous intravascular administration technique is required, particularly during angiographic procedures, to minimize thromboembolic events; this includes close attention to guidewire and catheter manipulation, use of manifold systems and\/or 3-way stopcocks, frequent catheter flushing with heparinized saline solutions, and minimizing the length of the procedure; plastic syringes in place of glass syringes may decrease, but not eliminate, the likelihood of clotting<\/li><li>use lowest dose necessary for adequate visualization<\/li><li>individualize dosing for each patient.<\/li><li>greatest contrast enhancement occurs within 60 to 90 seconds after bolus administration; continuous scanning technique (dynamic scanning) may improve enhancement<\/li><li><b>Angiocardiography:<\/b> (selective coronary artery) iopamidol injection 76% containing 370 mg iodine\/mL, 2 to 10 mL IV<\/li><li><b>Angiocardiography:<\/b> (multiple coronary arteries following aortic root injection) iopamidol injection 76% containing 370 mg iodine\/mL, 25 to 50 mL IV; MAX total dose when combined with ventriculography has not exceeded 200 mL<\/li><li><b>Angiocardiography:<\/b> (ventriculography) iopamidol injection 76% containing 370 mg iodine\/mL, 25 to 50 mL IV; MAX total dose when combined with coronary arteriography has not exceeded 200 mL<\/li><li><b>Aortography:<\/b> iopamidol injection 76% containing 370 mg iodine\/mL, doses up to 50 mL IV may be required but lower doses may be sufficient; MAX combined total dose for multiple injections has not exceeded 225 mL<\/li><li><b>Arteriography, peripheral:<\/b> (femoral or subclavian artery) iopamidol injection 61% containing 300 mg iodine\/mL, 5 to 40 mL IV; MAX total dose of 250 mL<\/li><li><b>Arteriography, peripheral:<\/b> (aortic distal runoff) iopamidol injection 61% containing 300 mg iodine\/mL, 25 to 50 mL IV  MAX total dose of 250 mL <\/li><li><b>Arteriography, Selective visceral:<\/b> iopamidol injection 76% containing 370 mg iodine\/mL, doses up to 50 mL IV may be required for larger vessels and doses up to 10 mL IV may be required for renal arteries; lower doses may be sufficient; MAX combined total dose for multiple injections has not exceeded 225 mL<\/li><li><b>Arteriography of cerebral arteries:<\/b> iopamidol injection 61% containing 300 mg iodine\/mL, 8 to 12 mL IV injection; MAX total multiple doses up to 90 mL<\/li><li><b>Computerized axial tomography, Head and Body:<\/b> (head) iopamidol injection 51% containing 250 mg iodine\/mL, 130 to 240 mL IV; MAX total dose not to exceed 60 g iodine<\/li><li><b>Computerized axial tomography, Head and Body:<\/b> (head) iopamidol injection 61% containing 300 mg iodine\/mL, 100 to 200 mL IV; MAX total dose not to exceed 60 g iodine<\/li><li><b>Computerized axial tomography, Head and Body:<\/b> (body) iopamidol injection 51% containing 250 mg iodine\/mL, 130 to 240 mL rapid IV infusion or bolus; MAX total dose not to exceed 60 g iodine<\/li><li><b>Computerized axial tomography, Head and Body:<\/b> (body) iopamidol injection 61% containing 300 mg iodine\/mL, 100 to 200 mL rapid IV infusion or bolus; MAX total dose not to exceed 60 g iodine<\/li><li><b>Computerized axial tomography, Head and Body:<\/b> (body) iopamidol injection 76% containing 370 mg iodine\/mL, equivalent doses based on iodine content may be used; MAX total dose not to exceed 60 g iodine<\/li><li><b>CT cisternography, including ventriculography:<\/b> iopamidol injection 41% (ISOVUE-M(R) 200) containing 200 mg iodine\/mL, 4 to 6 mL INTRATHECALLY<\/li><li><b>Intravenous pyelogram:<\/b> iopamidol injection 51% containing 250 mg iodine\/mL, 50 to 100 mL rapid IV<\/li><li><b>Intravenous pyelogram:<\/b> iopamidol injection 61% containing 300 mg iodine\/mL, 50 mL rapid IV<\/li><li><b>Intravenous pyelogram:<\/b> iopamidol injection 76% containing 370 mg iodine\/mL, 40 mL rapid IV<\/li><li><b>Myelogram:<\/b> iopamidol injection 41% (ISOVUE-M(R) 200) containing 200 mg iodine\/mL or iopamidol injection 61% (ISOVUE-M(R) 300 containing 300 mg iodine\/mL, 2000 to 3000 mg iodine INTRATHECALLY<\/li><li><b>Venography:<\/b> iopamidol injection 41% containing 200 mg iodine\/mL, 25 to 150 mL IV per lower extremity; MAX combined total dose for multiple injections not to exceed 350 mL<\/li><\/ul>"},"1":{"id":"6ii8s1b5","title":"Pediatric Dosing","mono":"<ul><li>ISOVUE(R)-200, 250, 300 and 370 are not for intrathecal use and special attention must be given to insure that these products are not inadvertently administered intrathecally; ISOVUE-M(R) 200 and 300 are approved for intrathecal use<\/li><li>meticulous intravascular administration technique is required, particularly during angiographic procedures, to minimize thromboembolic events; this includes close attention to guidewire and catheter manipulation, use of manifold systems and\/or 3-way stopcocks, frequent catheter flushing with heparinized saline solutions, and minimizing the length of the procedure; plastic syringes in place of glass syringes may decrease, but not eliminate, the likelihood of clotting<\/li><li>use lowest dose necessary for adequate visualization<\/li><li>individualize dosing for each patient.<\/li><li>greatest contrast enhancement occurs within 60 to 90 seconds after bolus administration; continuous scanning technique (dynamic scanning) may improve enhancement<\/li><li>in children, loss of contrast due to mixing on movement of the medium is less apt to occur because of their shorter spinal cord<\/li><li><b>Angiocardiography:<\/b> (single injection) iopamidol injection 76% containing 370 mg iodine\/mL, less than 2 years, 10 to 15 mL IV; 2 to 9 years, 15 to 30 mL IV; 10 to 18 years, 20 to 50 mL IV<\/li><li><b>Angiocardiography:<\/b> (cumulative injections) iopamidol injection 76% containing 370 mg iodine\/mL, less than 2 years, 40 mL IV; 2 to 4 years, 50 mL IV; 5 to 9 years, 100 mL IV; 10 to 18 years, 125 mL IV<\/li><li><b>Computerized axial tomography, Head and Body:<\/b> (head\/body), iopamidol injection 51% containing 250 mg iodine\/mL, 1.2 to 3.6 mL\/kg IV; MAX total dose not to exceed 30 g iodine<\/li><li><b>Computerized axial tomography, Head and Body:<\/b> (head\/body), iopamidol injection 61% containing 300 mg iodine\/mL, 1 to 3 mL\/kg IV; MAX total dose not to exceed 30 g iodine<\/li><li><b>Intravenous pyelogram:<\/b> iopamidol injection 51% containing 250 mg iodine\/mL, 1.2 to 3.6 mL\/kg IV; MAX total dose not to exceed 30 g iodine<\/li><li><b>Intravenous pyelogram:<\/b> iopamidol injection 61% containing 300 mg iodine\/mL, 1 to 3 mL\/kg IV; MAX total dose not to exceed 30 g iodine<\/li><li><b>Myelogram:<\/b> iopamidol injection 41% (ISOVUE-M(R) 200) containing 200 mg iodine\/mL, 2 to 7 years, 7 to 9 mL INTRATHECALLY; 8 to 12 years, 8 to 11 mL INTRATHECALLY; 13 to 18 years, 10 to 12 mL INTRATHECALLY<\/li><\/ul>"},"3":{"id":"6ii8s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Angiocardiography<\/li><li>Aortography<\/li><li>Arteriography, peripheral<\/li><li>Arteriography, Selective visceral<\/li><li>Arteriography of cerebral arteries<\/li><li>Computerized axial tomography, Head and Body<\/li><li>CT cisternography, including ventriculography<\/li><li>Intravenous pyelogram<\/li><li>Myelogram<\/li><li>Venography<\/li><\/ul>"}}},"3":{"id":"6ii8s3","title":"Contraindications\/Warnings","sub":[{"id":"6ii8s3b9","title":"Contraindications","mono":"<ul><li>Administration of intrathecal iopamidol with intrathecal corticosteroids<\/li><li>Immediate repeat myelography<\/li><li>Intrathecal administration in the presence of significant local or systemic infection where bacteremia is likely<\/li><\/ul>"},{"id":"6ii8s3b10","title":"Precautions","mono":"<ul><li>Patients should be well-hydrated prior to and following an iopamidol administration (intravascular administration)<\/li><li>Severely impaired renal function, combined renal and hepatic disease, or anuria, especially when higher doses are employed  (intravascular administration)<\/li><li>Multiple myeloma or other paraproteinemia, particularly in patients with therapeutically resistant anuria  (intravascular administration)<\/li><li>Patients with homozygous sickle cell disease (contrast media may promote sickling)  (intravascular administration)<\/li><li>Patients with known or suspected pheochromocytoma  (intravascular administration)<\/li><li>Hyperthyroid patients or patients with an autonomously functioning thyroid nodule  (intravascular administration)<\/li><li>Patients with a previous reaction to a contrast medium; patients with known sensitivity to iodine  (intravascular administration)<\/li><li>Patients with clinical hypersensitivity (asthma, hay fever, food allergy) are at greater risk of developing serious, anaphylactic reactions; pretesting does not delineate reliably the occurrence of severe reactions in these patients  (intravascular administration)<\/li><li>A positive history of allergies or hypersensitivity does not preclude the use of a contrast agent if the procedure is considered essential; however, premedication with antihistamines or steroids to avoid or minimize allergic reactions is suggested.  Although pretreatment may not prevent serious life-threatening reactions, it may reduce the incidence of severity of such reactions  (intravascular administration)<\/li><li>General anesthesia  (intravascular administration)<\/li><li>Congestive heart failure, due to hyperosmolality (intravascular administration)<\/li><li>Selective coronary arteriography should be performed only in selected patients where expected benefits outweigh the procedural risks.  A similar precaution exists for patients with chronic pulmonary emphysema who are to undergo angiocardiography. Angiography should be avoided in patients with homocystinuria (risk of inducing thrombosis and embolism)  (intravascular administration)<\/li><li>Iopamidol should not be mixed with any other drugs in IV admixtures  (intravascular administration)<\/li><li>Administer with caution in patients with increased intracranial pressure or suspicion of intracranial tumor, abscess or hematoma, those with a history of convulsive disorder, severe cardiovascular disease, chronic alcoholism, or multiple sclerosis, and elderly patients.  Particular attention must be given to state of hydration, concentration of medium, dose, and technique used in these patients (intrathecal administration)<\/li><li>If frankly bloody cerebrospinal fluid is observed, the possible benefits of the myelographic examination should be considered in terms of risk to the patient  (intrathecal administration)<\/li><li>Patients on anticonvulsant medication should be maintained on this therapy  (intrathecal administration)<\/li><li>Direct intracisternal or ventricular administration for standard radiography (without computerized tomographic enhancement) is not recommended.  Inadvertent intracranial entry of a large or concentrated bolus of the contrast medium, which increases the risk of neurotoxicity, can be prevented by careful patient management  (intrathecal administration)<\/li><li>Effort should be directed to avoid rapid dispersion of the medium causing inadvertent rise of intracranial levels (eg, by active patient movement).  If such intracranial entry of the medium occurs, prophylactic anticonvulsant treatment with diazepam or barbiturates orally for 24 to 48 hours should be considered  (intrathecal administration)<\/li><li>Use of medications that may lower the seizure threshold; while the contributory role of such medications has not been established, some physicians have discontinued these agents at least 48 hours before and for at least 24 hours following intrathecal use  (intrathecal administration)<\/li><li>AVOID (intrathecal administration): deviations from recommended neuroradiologic procedure or patient management; use in patients with a history of epilepsy unless medically justified; overdosage; intracranial entry of a bolus or premature diffusion of a high concentration of the medium; failure to maintain elevation of the head during the procedure, on the stretcher, and in bed; excessive and particularly active patient movement or straining<\/li><\/ul>"},{"id":"6ii8s3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"6ii8s3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"6ii8s4","title":"Drug Interactions","sub":[{"id":"6ii8s4b13","title":"Contraindicated","mono":"<ul>Metformin (theoretical)<\/ul>"}]},"5":{"id":"6ii8s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Burning sensation (intrathecal, less than or equal to 1%; intravascular, 1.4%), Flushing, Hot flashes (intrathecal, less than or equal to 1%; intravascular, up to 3.4%), Injection site pain (intravascular, frequent)<\/li><li><b>Gastrointestinal:<\/b>Nausea (intrathecal, 7.3%; intravascular, 1.2%), Vomiting (intrathecal, 3.6%; intravascular, less than or equal to 1%)<\/li><li><b>Musculoskeletal:<\/b>Backache (intrathecal, 2.2%), Neck pain (intrathecal, 1.1%), Pain, In legs (intrathecal, 1.4%)<\/li><li><b>Neurologic:<\/b>Headache (intrathecal, 16.4%; intravascular, less than or equal to 1%)<\/li><li><b>Other:<\/b>Pain (intravascular, 2.8%), Sensation of hot and cold (intravascular, 1.1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia, Cardiorespiratory arrest, Decompensated cardiac failure, Myocardial ischemia<\/li><li><b>Endocrine metabolic:<\/b>Thyroid storm<\/li><li><b>Hematologic:<\/b>Thromboembolic disorder<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Seizure<\/li><\/ul>"},"6":{"id":"6ii8s6","title":"Drug Name Info","sub":{"0":{"id":"6ii8s6b17","title":"US Trade Names","mono":"<ul><li>Isovue-200<\/li><li>Isovue-250<\/li><li>Isovue-300<\/li><li>Isovue-370<\/li><li>Isovue-M 200<\/li><li>Isovue-M 300<\/li><\/ul>"},"2":{"id":"6ii8s6b19","title":"Class","mono":"Radiological Non-Ionic Contrast Media<br\/>"},"3":{"id":"6ii8s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"6ii8s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"6ii8s7","title":"Mechanism Of Action","mono":"Systemic: Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine.   The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of iopamidol in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, iopamidol makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs.  <br\/>"},"8":{"id":"6ii8s8","title":"Pharmacokinetics","sub":{"3":{"id":"6ii8s8b26","title":"Excretion","mono":"<ul><li>Systemic: Intrathecal- Renal; 29 to 100% unchanged<\/li><li>Intravascular- Renal: 80 to 90% unchanged<\/li><\/ul>"},"4":{"id":"6ii8s8b27","title":"Elimination Half Life","mono":"Systemic: 2 h <br\/>"}}},"9":{"id":"6ii8s9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>use only if solution is clear within normal range of colorless to pale yellow<\/li><li>discard if signs of crystallization or damage to container closure system, including the glass container, stopper, or crimp<\/li><li>(imaging bulk package) dispenses doses to multiple patients using automated contrast injection system or contrast management system; use only in room designated for procedures requiring intravascular contrast<\/li><li>(imaging bulk package) puncture container only once and do not remove from room; keep bottle inverted to ensure contents maintain contact with dispensing set<\/li><li>(imaging bulk package) discard 10 hours after puncture or if direct continuous supervision is not maintained to assure product integrity<\/li><li>(pharmacy bulk package) use with transfer device to fill sterile syringes in a laminar airflow hood or other suitable environment<\/li><li>(pharmacy bulk package) puncture container only once and do not remove from work area after puncture<\/li><li>(pharmacy bulk package) discard 10 hours after puncture<\/li><li>solution should be at body temperature when injected<\/li><li>patients should be well hydrated prior to and following administration<\/li><\/ul>"},"11":{"id":"6ii8s11","title":"How Supplied","mono":"<ul><li><b>Isovue-200<\/b><br\/>Injection Solution: 41 %<br\/><\/li><li><b>Isovue-250<\/b><br\/>Injection Solution: 51 %<br\/><\/li><li><b>Isovue-300<\/b><br\/>Injection Solution: 61 %<br\/><\/li><li><b>Isovue-370<\/b><br\/>Injection Solution: 76 %<br\/><\/li><li><b>Isovue-M 200<\/b><br\/>Injection Solution: 41 %<br\/><\/li><li><b>Isovue-M 300<\/b><br\/>Injection Solution: 61 %<br\/><\/li><li><b>Isovue Multipack-250<\/b><br\/>Injection Solution: 51 %<br\/><\/li><li><b>Isovue Multipack-300<\/b><br\/>Injection Solution: 61 %<br\/><\/li><li><b>Isovue Multipack-370<\/b><br\/>Injection Solution: 76 %<br\/><\/li><\/ul>"}}}